Physiogenex is a proud sponsor of the Hanson Wade 1st Type 2 diabetes & Obesity Therapeutics Summit to be held in Boston, May 30th – June 1st, 2023:
On June 1st 9:20am, Dr. François Briand, our Director of Research and Business Development, will be presenting how Physiogenex drives the transition from a Simple Diet-Induced Obese Mouse to Animal Models With Multiple Comorbidities to successfully develop and differentiate drugs targeting obesity/type 2 diabetes.
After his 10-minute oral presentation, François Briand will be joining the experts and industry key opinion leaders Dr. Jacob Jeppesen from Novo Nordisk and Dr. Steve Faraci from Cyta Therapeutics for a panel discussion on the best preclinical models and strategies to better recapitulate obesity, type 2 diabetes, and associated cardiometabolic complications.
New data on GLP-1 receptor agonism benefits in the SDT fatty rat model will be also presented by François Briand during the Drinks Reception & Scientific Poster Session on May the 30th.
Feel free to contact us if you wish to set-up an appointment with Dr. Briand and/or discuss your drug development projects with us.
About us
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.